Tobramycin

Medical uses

Tobramycin does not pass the gastro-intestinal tract, so for systemic use it can only be given intravenously or by injection into a muscle. Eye drops and ointments (tobramycin only, Tobrex, or combined with dexamethasone, sold as Tobradex) and nebulised formulations both have low systemic absorption. The formulation for injection is branded Nebcin. The nebulised formulation (brand name Tobi) is indicated in the treatment of exacerbations of chronic infection with Pseudomonas aeruginosa in people diagnosed with cystic fibrosis.

Tobramycin eye drops (with or without dexamethasone) are indicated in the treatment of superficial infections of the eye, such as bacterial conjunctivitis.

Tobramycin, in its injectable form, is also indicated for various severe or life-threatening infections caused by susceptible strains: sepsis, meningitis, lower respiratory tract infections, intra-abdominal infections, skin infections, bone infections, and skin structure infections, complicated and recurrent urinary tract infections.

Spectrum of susceptibility

Tobramycin has a narrow spectrum of activity and is active against Gram-positive Staphylococcus aureus and various Gram-negative bacteria. Clinically, tobramycin is frequently used to eliminate Pseudomonas aeruginosa in cystic fibrosis patients. The following represents the minimum inhibitory concentration (MIC) susceptibility data for a few strains of Pseudomonas aeruginosa:

• Pseudomonas aeruginosa -
• Pseudomonas aeruginosa (non-mucoid) – 0.5 μg/mL - 512 μg/mL
• Pseudomonas aeruginosa (ATCC 27853) – 0.5 μg/mL – 2 μg/mL The MIC for Klebsiella pneumoniae, KP-1, is 2.3±0.2 μg/mL at 25 °C [unpublished].

Contraindications

Tobramycin is contraindicated in people with hypersensitivity against aminoglycoside antibiotics. The Infusion is also contraindicated in people with myasthenia gravis.

Side effects

Like other aminoglycosides, a major side effect for tobramycin is ototoxicity or a loss of equilibrioception, or both in genetically susceptible individuals. Other side effects include nephrotoxicity, neuromuscular toxicity, and hypersensitivity reactions. Nephrotoxicity can be particularly worrisome when multiple doses accumulate over the course of a treatment or when the kidney concentrates urine by increasing tubular reabsorption during sleep. Adequate hydration may help prevent excess nephrotoxicity and subsequent loss of renal function. For these reasons parenteral tobramycin needs to be carefully dosed by body weight, and its serum concentration monitored. Tobramycin is thus said to be a drug with a narrow therapeutic index.

Interactions

Muscle relaxants and diethylether can add to the neuromuscular blocking effects of tobramycin.

Methoxyflurane, when used as an inhalational anesthetic, can aggravate the nephrotoxic effects of injected tobramycin. Likewise, combining injected tobramycin with other nephrotoxic or ototoxic drugs can lead to more adverse effects; examples include amphotericin B, ciclosporin, cisplatin, vancomycin, and the diuretic furosemide. Other diuretics can also increase the risk for side effects because they raise tobramycin concentrations in the body fluids.

Combining tobramycin with beta-lactam antibiotics can be desirable because of their synergistic effects. However, when they are given through the same drip, as well as in people with reduced kidney function, they can react with each other to form antibiotically inactive amides.

Pharmacology

Mechanism of action

Tobramycin works by binding to a site on the bacterial 30S and 50S ribosome, preventing formation of the 70S complex. As a result, mRNA cannot be translated into protein, and cell death ensues. Tobramycin also binds to RNA-aptamers, artificially created molecules to bind to certain targets. However, there seems to be no indication that Tobramycin binds to natural RNAs or other nucleic acids.

The effect of tobramycin can be inhibited by metabolites of the Krebs (TCA) cycle, such as glyoxylate. These metabolites protect against tobramycin lethality by diverting carbon flux away from the TCA cycle, collapsing cellular respiration, and thereby inhibiting Tobramycin uptake and thus lethality.

Pharmacokinetics

Tobramycin is not absorbed in the gut. When given as infusion, it is distributed in the extracellular fluid. It can accumulate in the kidney's tubular cells and in the lymph of the inner ear. Only low concentrations reach the central nervous system and breast milk. Tobramycin passes the placenta: in the fetus, 20% of the mother's concentrations have been measured.

The substance is neither bound to plasma proteins, nor is it metabolized. It is excreted in unchanged form via the kidneys with a biological half-life of about 2 to 3 hours. Elimination from deep compartments such as the renal cortex follows after 8 to 12 hours. In newborns the half-life is 4.6 hours on average; in those with a low birth weight it is as long as 8.7 hours on average. People with reduced kidney function also have a longer half-life for tobramycin, while in those with severe burns it can be shorter.

Society and culture

Tobramycin was patented in 1965, and approved for medical use in 1974. Tobramycin is on the World Health Organization's List of Essential Medicines. In 2023, tobramycin was the 298th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.

Tobrex eye drops are a 0.3% tobramycin sterile ophthalmic solution produced by Alcon Pharmaceuticals. Benzalkonium chloride 0.01% is added to Tobrex as a preservative.

Brand names

In Egypt, tobramycin (in the form of eye drops) is sold under the brand Tobrin, produced by EIPICo.

References

References

1. (11 November 2019). "Tobramycin Use During Pregnancy".
2. (24 December 2019). "Tobramycin ophthalmic Use During Pregnancy".
3. (21 June 2022). "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017".
4. (February 2024). "Product monograph brand safety updates".
5. (9 October 2018). "Tobramycin 40mg/mL Injection – Summary of Product Characteristics (SmPC)".
6. (17 March 2003). "Tobi Podhaler EPAR".
7. (2021). "Austria-Codex". Österreichischer Apothekerverlag.
8. (12 January 2010). "Tobramycin". Toku-E.
9. (2006). "Analogue-based Drug Discovery". John Wiley & Sons.
10. (2023). "The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023)". World Health Organization.
11. "The Top 300 of 2023".
12. "Tobramycin Drug Usage Statistics, United States, 2014 - 2023".
13. (5 October 2018). "Tobi- tobramycin solution".
14. (17 September 2018). "Tobi Podhaler".
15. (16 September 2019). "Tobrex- tobramycin ointment".
16. (21 January 2020). "Tobradex Eye Drops – Summary of Product Characteristics (SmPC)".
17. (11 September 2019). "Tobradex- tobramycin and dexamethasone ointment".
18. (9 September 2019). "Tobradex- tobramycin and dexamethasone suspension/ drops".
19. (11 October 2019). "Tobramycin- tobramycin sulfate injection, powder, for solution".
20. "Tobramycin Susceptibility and Minimum Inhibitory Concentration (MIC) Data". Toku-E.
21. (2021). "Austria-Codex". Österreichischer Apothekerverlag.
22. (May 1983). "Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin". Lancet.
23. (August 1976). "Tobramycin: an overview". The Journal of Infectious Diseases.
24. (April 1987). "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis". Antimicrobial Agents and Chemotherapy.
25. (January 2022). "StatPearls". StatPearls Publishing.
26. (September 2006). "Binding of aminoglycosidic antibiotics to the oligonucleotide A-site model and 30S ribosomal subunit: Poisson-Boltzmann model, thermal denaturation, and fluorescence studies". Journal of Medicinal Chemistry.
27. (April 2002). "Design of novel antibiotics that bind to the ribosomal acyltransfer site". Journal of the American Chemical Society.
28. (December 2000). "Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance". Antimicrobial Agents and Chemotherapy.
29. (February 2017). "Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control". Cell Chemical Biology.